The BLA for mRNA-1083 will be resubmitted later this year once vaccine efficacy data from an ongoing phase 3 trial assessing mRNA-1010 are available. Moderna has withdrawn the Biologics License ...
Inovio Pharmaceuticals (INO) had a slight setback with its timeline on when it could actually file its Biologics License Application [BLA] of INO-3107 for the treatment of patients with recurrent ...
The company raised its full-year 2025 revenue growth guidance to "at least 17% or revenue of at least $219 million." Gross margin guidance remains in the "range of 73% to 75%, inclusive of onetime ...
Detailed price information for Os Therapies Incorporated (OSTX-A) from The Globe and Mail including charting and trades.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results